Tags

Type your tag names separated by a space and hit enter

Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders.

Abstract

Agents acting via cannabinoid receptors have been widely developed; starting from the chemical structure of phytocannabinoids isolated from cannabis sativa plant, specific and selective compounds of these receptors have been produced ranging from partial to full agonists and /or antagonists endowed with different potency. The enhanced interest on developing such classes of drugs is due to the beneficial properties widely reported by both anecdotal reports and scientific studies describing the potential medicinal use of cannabinoids and their derivatives in numerous pathological conditions in both in vitro and in vivo models. The use of these drugs has been found to be of benefit in a wide number of neurological and neuropsychiatric disorders, and in many other diseases ranging from cancer, atherosclerosis, stroke, hypertension, inflammatory related disorders, and autoimmune diseases, just to mention some. In particular, being the cannabinoid CB1 receptor a central receptor expressed by neurons of the central nervous system, the attention for the treatment of neurological diseases has been mainly focused on compounds acting via this receptor, however some of these compounds has been showed to act by alternative pathways in some cases unrelated to CB1 receptors. Nonetheless, endocannabinoids are potent regulators of the synaptic function in the central nervous system and their levels are modulated in neurological diseases. In this study, we focused on endocannabinoid mechanism of action in neuronal signaling and on cannabimimetic drug potential application in neurological disorders. Finally, novel patents on cannabis-based drugs with applicability in central nervous system disorders are highlighted, to suggest future potential therapeutic utility of derivatives of this ancient plant.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableNo affiliation info availableDepartment of Medicine and Surgery, University of Salerno, Via Salvatore Allende, Baronissi, 84081 Salerno, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27334611

Citation

Ranieri, Roberta, et al. "Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders." Recent Patents On CNS Drug Discovery, 2016.
Ranieri R, Marasco D, Bifulco M, et al. Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. Recent Pat CNS Drug Discov. 2016.
Ranieri, R., Marasco, D., Bifulco, M., & Malfitano, A. M. (2016). Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. Recent Patents On CNS Drug Discovery.
Ranieri R, et al. Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. Recent Pat CNS Drug Discov. 2016 Jun 19;. PubMed PMID: 27334611.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders. AU - Ranieri,Roberta, AU - Marasco,Daniela, AU - Bifulco,Maurizio, AU - Malfitano,Anna Maria, Y1 - 2016/06/19/ PY - 2015/12/21/received PY - 2016/02/22/revised PY - 2016/06/23/accepted PY - 2016/6/24/entrez PY - 2016/6/24/pubmed PY - 2016/6/24/medline SP - EP - JF - Recent patents on CNS drug discovery JO - Recent Pat CNS Drug Discov N2 - Agents acting via cannabinoid receptors have been widely developed; starting from the chemical structure of phytocannabinoids isolated from cannabis sativa plant, specific and selective compounds of these receptors have been produced ranging from partial to full agonists and /or antagonists endowed with different potency. The enhanced interest on developing such classes of drugs is due to the beneficial properties widely reported by both anecdotal reports and scientific studies describing the potential medicinal use of cannabinoids and their derivatives in numerous pathological conditions in both in vitro and in vivo models. The use of these drugs has been found to be of benefit in a wide number of neurological and neuropsychiatric disorders, and in many other diseases ranging from cancer, atherosclerosis, stroke, hypertension, inflammatory related disorders, and autoimmune diseases, just to mention some. In particular, being the cannabinoid CB1 receptor a central receptor expressed by neurons of the central nervous system, the attention for the treatment of neurological diseases has been mainly focused on compounds acting via this receptor, however some of these compounds has been showed to act by alternative pathways in some cases unrelated to CB1 receptors. Nonetheless, endocannabinoids are potent regulators of the synaptic function in the central nervous system and their levels are modulated in neurological diseases. In this study, we focused on endocannabinoid mechanism of action in neuronal signaling and on cannabimimetic drug potential application in neurological disorders. Finally, novel patents on cannabis-based drugs with applicability in central nervous system disorders are highlighted, to suggest future potential therapeutic utility of derivatives of this ancient plant. SN - 2212-3954 UR - https://www.unboundmedicine.com/medline/citation/27334611/Cannabimimetic_Drugs:_Recent_Patents_in_Central_Nervous_System_Disorders_ L2 - http://www.eurekaselect.com/143435/article DB - PRIME DP - Unbound Medicine ER -